Trials / Completed
CompletedNCT01304147
Intranasal Ketamine in Treatment-Resistant Depression
Intranasal (IN) Ketamine in Treatment-Resistant Depression (TRD)
- Status
- Completed
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 20 (actual)
- Sponsor
- James Murrough · Academic / Other
- Sex
- All
- Age
- 21 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The objective of the current study is to investigate the safety and efficacy of a single dose of intranasal (IN) ketamine in treatment-resistant depression (TRD).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ketamine | A single dose of intranasal ketamine up to 50 mg |
| DRUG | placebo | Single dose of saline intranasal |
Timeline
- Start date
- 2011-10-01
- Primary completion
- 2014-10-01
- Completion
- 2014-10-01
- First posted
- 2011-02-25
- Last updated
- 2017-02-08
- Results posted
- 2017-02-08
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT01304147. Inclusion in this directory is not an endorsement.